$70.93 -1.49 (%) Cubist Pharmaceuticals Inc - NASDAQ

Oct. 24, 2014 | 04:00 PM

Partner Headlines

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  2. Benzinga's Weekend M&A Chatter

    Benzinga | Oct. 19, 2014 | 21:58PM EST
  3. Actavis expands antibiotics

    IBD | Oct. 6, 2014 | 18:45PM EST
  4. Actavis Expands Antibiotics Presence With Durata Buy

    IBD | Oct. 6, 2014 | 10:58AM EST
  5. Morning Market Losers

    Benzinga | Jul. 23, 2014 | 09:52AM EST
  6. Jefferies Raises Price Target On Cubist Pharmaceuticals

    Benzinga | Jun. 23, 2014 | 15:40PM EST
  7. Benzinga's Top #PreMarket Gainers

    Benzinga | Jun. 23, 2014 | 08:07AM EST
  8. Cubist Readies For Takeoff With New Antibiotic Launch

    IBD | Jun. 19, 2014 | 17:23PM EST
  9. Cubist Pharma Reports Publicant of Pivotal Data from SIVEXTRO ESTABLISH-2 Trial

    Benzinga | Jun. 6, 2014 | 09:01AM EST
  10. Morning Market Movers

    Benzinga | Apr. 29, 2014 | 09:43AM EST
  11. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 29, 2014 | 08:09AM EST
  12. Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium

    GuruFocus | Apr. 23, 2014 | 16:46PM EST
  13. Credit Suisse Maintains on Cubist Pharmaceuticals

    Benzinga | Jan. 24, 2014 | 09:22AM EST
  14. Cubist Submits CTA to Dutch Competent Authority and Ethics Committee to Initiate First-in-Human Study of CB-618

    Benzinga | Jan. 10, 2014 | 11:08AM EST
  15. Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review

    Benzinga | Dec. 30, 2013 | 07:38AM EST
  16. Cubist Announces FDA Accepts Tedizolid NDA with Priority Review

    Benzinga | Dec. 30, 2013 | 07:36AM EST
  17. Cubist drug passes 2nd test

    IBD | Dec. 16, 2013 | 18:48PM EST
  18. Cubist Antibiotic Passes Second Test; FDA Filing Next

    IBD | Dec. 16, 2013 | 11:18AM EST
  19. Stock Futures Sharply Higher; AerCap Surges On Acquisition

    IBD | Dec. 16, 2013 | 09:07AM EST
  20. Cubist antibiotic passes test

    IBD | Nov. 25, 2013 | 18:44PM EST
  21. Cubist Antibiotic Shines In Trials; Stock Jumps

    IBD | Nov. 25, 2013 | 11:34AM EST
  22. Michael Price's Top Sells - 11 Gurus Exit SFD

    GuruFocus | Nov. 19, 2013 | 11:53AM EST
  23. Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

    Benzinga | Nov. 7, 2013 | 04:19AM EST
  24. UPDATE: Wedbush Downgrades Cubist Pharmaceuticals Following Slight Q3:13 Results Miss

    Benzinga | Oct. 24, 2013 | 10:36AM EST
  25. Stocks Open Down In Firm Trade; Cree Crumbles On Q3 Results

    IBD | Oct. 23, 2013 | 10:36AM EST
  26. Cubist Pharma Announces Submission of NDA for Tedizolid for Treatment of Serious Skin Infections

    Benzinga | Oct. 22, 2013 | 08:35AM EST
  27. Cubist Announces FDA Approval for Expanded Use of ENTEREG

    Benzinga | Oct. 21, 2013 | 08:04AM EST
  28. UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong Antibiotic Portfolio

    Benzinga | Oct. 10, 2013 | 09:37AM EST
  29. UPDATE: Mizuho Securities Upgrades Cubist Pharmaceuticals on Pending Acquisitions of Optimer and Trius

    Benzinga | Oct. 9, 2013 | 11:51AM EST
  30. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin

    Benzinga | Oct. 7, 2013 | 04:38AM EST
  31. UPDATE: Leerink Swann Upgrades Cubist Pharmaceuticals Following Acquisition of TSRX

    Benzinga | Sep. 26, 2013 | 10:23AM EST
  32. Benzinga's Top Upgrades

    Benzinga | Sep. 26, 2013 | 07:48AM EST
  33. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

    Benzinga | Sep. 26, 2013 | 05:13AM EST
  34. HSR Waiting Period Expires for Cubist, Optimer Deal

    Benzinga | Sep. 13, 2013 | 08:32AM EST
  35. Cubist Pharmaceuticals Issues $800M of Convertible Senior Notes

    Benzinga | Sep. 10, 2013 | 16:01PM EST
  36. Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M

    Benzinga | Sep. 5, 2013 | 08:06AM EST
  37. UPDATE: Aegis Capital Upgrades Cubist Pharmaceuticals Following Trius/Optimer Acquisitions Announcement

    Benzinga | Aug. 2, 2013 | 09:42AM EST
  38. Benzinga's Top Upgrades

    Benzinga | Aug. 2, 2013 | 07:44AM EST
  39. Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Green Dot Rises

    Benzinga | Jul. 31, 2013 | 15:45PM EST
  40. UPDATE: Cantor Fitzgerald Raises PT on Cubist Pharmaceuticals

    Benzinga | Jul. 31, 2013 | 13:55PM EST
  41. Mid-Day Market Update: Questcor Shares Jump On Upbeat Earnings, Riverbed Drops

    Benzinga | Jul. 31, 2013 | 12:39PM EST
  42. Mid-Morning Market Update: Markets Open Higher, MasterCard Profit Tops Estimates

    Benzinga | Jul. 31, 2013 | 10:49AM EST
  43. UPDATE: Goldman Sachs Downgrades Cubist Pharmaceuticals Following Removal from Conviction List

    Benzinga | Jul. 31, 2013 | 09:37AM EST
  44. Benzinga's Top Pre-Market Losers

    Benzinga | Jul. 31, 2013 | 08:18AM EST
  45. Benzinga's Top Pre-Market Gainers

    Benzinga | Jul. 31, 2013 | 08:11AM EST
  46. Benzinga's Top Upgrades

    Benzinga | Jul. 31, 2013 | 07:50AM EST
  47. Benzinga Market Primer: Wednesday, July 31: Futures Higher Heading Into FOMC Decision

    Benzinga | Jul. 31, 2013 | 06:33AM EST
  48. Cubist Announces Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals (CBST, OPTR, TSRX)

    Benzinga | Jul. 30, 2013 | 18:10PM EST
  49. Benzinga's M&A Chatter for Tuesday July 30, 2013

    Benzinga | Jul. 30, 2013 | 17:41PM EST
  50. Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals For $10.75 In Cash

    Benzinga | Jul. 30, 2013 | 16:46PM EST
Trading Center